Monoclonal antibody BR110 and uses thereof

Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

5303873, 5303882, 5303913, 5303917, 435328, 435330, 4351722, 4241331, 4241381, 4241551, 4241811, A61K 31395

Patent

active

058408541

ABSTRACT:
The present invention provides internalizing ligands (i.e., BR110 ligands) which specifically recognize and bind the BR110 antigen. After binding the antigen, the ligand and antigen form a complex. As a complex, the antigen can be detected using well known and developed methods and commercial systems.

REFERENCES:
patent: 5185254 (1993-02-01), Linnenbach
Marglin et al Ann Rev Biochem vol. 39: 841-866, 1970.
Fanger et al FASEB Journal vol. 4 2846-2849, 1990.
Paul, WE Fundamental Immunology Third Edition p. 242,1993.
Osband et al Immunology Today vol. 11 No.6:193-195, 1990.
Waldmann Science vol. 252:1657-1661, 1991.
Dillman Annals of Internal Medicine vol. 111 592-603, 1989.
Seaver Genetic Engineering vol. 14 (14) p. 10 and 21, 1994.
Stein et al Cancer Research vol. 50 1330-1336, 1990.
Fradet et al Proc Nat Acad Sci USA vol. 81 224-228, Jan. 1984.
Miotti et al int J Cancer vol. 39 297-303, 1987.
Alberti et al Hybridoma vol. 11 No. 5 539-545, 1992.
Fornaro et al, Int J Cancer vol. 62 610-618, 1995.
Lerner et al Nature vol. 229:592-596, 1992.
Galfre et al Methods in Enzymology vol. 73 1-46, 1981.
Reichmann et al Nature vol. 332 323-327, Mar. 1988.
Blakey et al Monoclonal Antibody Therapy Prog Allergy Basel Karger vol. 45 50-90, 1988.
Zuckier et al Seminars in Nuclear Medicine vol. XIX 166-186, Jul. 1989.
Bird et al Science vol. 241 423-426, Oct. 1988.
Casalini, P. et al. (1993) A critical comparison of three internalization assays applied to the evaluation of a given mAb as a toxin-carrier candidate, Cancer Immunol. Immunother. 37:54-60.
Herlyn, D. et al. (1986) Anti-idiotypic antibodies bear the internal image of a human tumor antigen, Science 232:100-102.
Herlyn, D. et al. (1986) Hybridoma, 5:S3-S10.
Linnenbach, A.J. et al. (1989) Sequence investigation of the major gastrointestinal tumor-associated antigen gene family, GA733, Proc. Natl. Acad. Sci. USA 86:27-31.
Szala, S. et al. (1990) Molecular cloning of a cDNA for the carcinoma-associated antigen GA733-2, Proc Natl. Acad. Sci. USA 87:3542-3546.
Rakowicz-Szulczynska, E.M. et al. (1992) Nuclear translocation of monoclonal antibody directed against cell-surface carbohydrate Y determinant, American Journal of Pathology 141(4):937-947.
Stein, R. et al., "Characterization of Cluster 13: The Epithelial/Carcinomas Antigen Recognized by Mab RS7", Internation Journal of Cancer: Supplement, 1994, vol. 8, pp. 98-102.
De Leij, L. et al., "SCLC-Cluster-2 Antibodies Detect the Pancarcinoma/Epithelial Glycoprotein EGP-2", International Journal of Cancer: Supplement, 1994, vol. 8, pp. 60-63.
Stein, R. et al., "Specificity and Properties of Mab RS7-3G11 and the Antigen Defined by This Pancarcinoma Monoclonal Antibody", Internation Journal of Cancer, Dec. 2, 1993, vol. 55, pp. 938-946.
Friedman P. N. et al., "Antitumor Activity of the Single Chain Immunotoxin BR96 sFv-PE40 Against Established Breast and Lung Tumor Xenografts", Journal of Immunology, Apr. 1993, vol. 150, No. 7, pp. 3054-3061.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Monoclonal antibody BR110 and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Monoclonal antibody BR110 and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibody BR110 and uses thereof will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-1703533

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.